title: [Modern approaches to the treatment of patients with overactive bladder and urge urinary incontinence].
abstract: Overactive bladder (OAB) is found in 20% of patients with various disorders of urination, and the imperative urinary incontinence diagnosed in one third of these patients. The study was aimed to improvement the treatment outcomes in OAB women with imperative incontinence and obstructive urination disorders by using a combination of alpha1-adrenoblockers and PDE-5 inhibitors, and to evaluation of relationship between clinical and urodynamic manifestations of the disease. The state of the microcirculation of the bladder mucosa before and after treatment was also evaluated. We have examined and treated 40 women aged 17 to 69 years with disease duration ranged from 1 to 20 years. Patients received combination of al-adrenoblocker alfuzosin (dalfaz) 5 mg at night and reversible selective PDE5 inhibitor tadalafil (Cialis) 5 mg daily in the morning for a month. After treatment, according to the uroflowmetry and cystometry data, the time of urination was reduced, urinary volume and maximum urinary flow rate, as well as cystometric capacity have increased; involuntary detrusor contractions in the bladder filling phase (spontaneous or provoked) became less, or absent. According to the results of ultrasound examination, residual urine volume has decreased. Laser Doppler flowmetry showed an increase of neurogenic tone in precapillary, bypass coefficient and microcirculation effectiveness index, increase in microcirculation index and the coefficient of variation, indicating an improvement of microcirculation in the bladder mucosa. As a result of treatment, the clinical effect was seen in 29 (73%) patients, urinary incontinence was noted only in 6 (15%) patients.
authors: M V
authors: MV
authors: Razdorskaia
authors: A I
authors: AI
authors: Neĭmark
authors: R T
authors: RT
authors: Aliev
mesh_terms: D000293:Adolescent; D058671:Adrenergic beta-1 Receptor Antagonists / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D002243:Carbolines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D017078:Laser-Doppler Flowmetry; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D009092:Mucous Membrane / Q000098:blood supply / Q000503:physiopathology; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage*; D011799:Quinazolines / Q000008:administration & dosage*; D000068581:Tadalafil; D001743:Urinary Bladder / Q000098:blood supply / Q000503:physiopathology; D053201:Urinary Bladder, Overactive / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D053202:Urinary Incontinence, Urge / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D002243:Carbolines; D058986:Phosphodiesterase 5 Inhibitors; D011799:Quinazolines; D000068581:Tadalafil; C047638:alfuzosin